LISA BURGESS: Open Payments
NPI 1073132502 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,972 in 135 payments from 18 companies in 2025. Trend: 2023 $1,752 · 2024 $2,855 · 2025 $1,972
Food & beverage: $1,972
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $373 |
| Janssen Biotech, Inc. | 13 | $281 |
| Celltrion USA Inc. | 23 | $214 |
| Gilead Sciences, Inc. | 10 | $206 |
| PFIZER INC. | 14 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $96 |
| Phathom Pharmaceuticals, Inc. | 7 | $90 |
| GENZYME CORPORATION | 3 | $82 |
| Intercept Pharmaceuticals, Inc. | 4 | $80 |
| Novo Nordisk Inc | 3 | $78 |
Products named: TREMFYA, VEGZELMA, RINVOQ, DUPIXENT, XELJANZ, ENTYVIO, VOQUEZNA, OCALIVA.
Industry payments across SC — which companies pay providers there.
